We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rubella IgG Assay Launched

By HospiMedica staff writers
Posted on 26 Mar 2007
An assay has been launched that aids in the determination of immunity to rubella infection, commonly known as German measles.

The Vitros Rubella IgG assay1 determines if IgG antibodies to the rubella virus are in the blood. More...
The presence of IgG antibodies may indicate a recent or past rubella infection or that a rubella vaccine has been given and is providing adequate protection. The Vitros ECi/ECiQ immunodiagnostic system is a simple-to-use, flexible, and fully-automated
laboratory testing system that provides true continuous STAT, random access capabilities for routine and specialty immunodiagnostic testing. The system uses proprietary enhanced chemiluminescence detection.

Rubella is a viral infection that manifests itself as a mild rash on the skin and a low-grade fever. It is primarily transmitted via droplets from the nose or throat that others inhale. It is also transmitted from a pregnant woman's bloodstream to the unborn child. It is generally a mild disease in children and healthy adults. However, there can be significant medical danger if a pregnant woman has an active infection and the developing unborn child becomes infected. This can lead to death of the unborn child or birth defects such as blindness, deafness, metal retardation, and cardiac abnormalities. The risk of fetal infection and the severity of defects are greatest during the first trimester.

Ortho-Clinical Diagnostics (Raritan, NJ, USA), a Johnson & Johnson company, announced U.S. Food and Drug Administration (FDA) clearance and availability of the Vitros rubella IgG assay1. The Vitros ECi/ECiQ immunodiagnostic system uses Intellicheck technology, a technology designed to verify diagnostic checks throughout automated sample and assay processing. Intellicheck serves to increase the integrity and security of reported patient results while helping to ensure greater confidence and productivity for laboratories that generate these results.

"Even though the incidence of rubella infections [is at a] record low, routine rubella IgG testing is a vital part of pre-natal screening to determine the immune status of females planning pregnancy” said Michael Waller, M.D., vice president, clinical and medical affairs for Ortho-Clinical Diagnostics. "Once the results are known, appropriate vaccination or precautions can be made.”


Related Links:
Ortho-Clinical Diagnostics

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical Examination & Procedure Light
Vega 80
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.